LENALIDOMIDE-DEXAMETHSONE (RD) VS MELPHALAN-LENALIDOMIDE-PREDNISONE (MPR) VS CYCLOPHOSPHAMIDE-PREDNISONE-LENALIDOMIDE (CPR) IN ELDERLY COMMUNITY-BASED NEWLY DIAGNOSED MYELOMA PATIENTS

被引：0
|
作者：
Magarotto, V. [1 ]
Bringhen, S. [1 ]
Hajek, R. [2 ,3 ]
Musto, P.
Goldaniga, M. C.
Ledda, A.
De Rosa, L.
Patriarca, F.
Morabito, F.
Troia, R. [1 ]
Genuardi, M. [1 ]
Berno, T.
Gambella, M. [1 ]
Pescosta, N.
Maisnar, V. [4 ,5 ]
Galli, M.
Falcone, A. P.
Rossi, D.
Offidani, M.
Boccadoro, M. [1 ]
Palumbo, A. [1 ]
机构：
[1] Univ Turin, Div Hematol, Myeloma Unit, Turin, Italy
[2] Univ Hosp Brno, Ostrava, Czech Republic
[3] Fac Med OU, Ostrava, Czech Republic
[4] Charles Univ Hradec Kralove, Fac Hosp, Dept Med 4, Hradec Kralove, Czech Republic
[5] Charles Univ Hradec Kralove, Fac Med, Hradec Kralove, Czech Republic
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P349
引用
收藏
页码：103 / 104
页数：2
相关论文
共 50 条
  • [21] MELPHALAN/PREDNISONE/LENALIDOMIDE (MPR) VERSUS HIGH-DOSE MELPHALAN AND AUTOLOGOUS TRANSPLANTATION (MEL200) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS
    Palumbo, A.
    Cavallo, F.
    Gay, F.
    di Toritto, T.
    Cavalli, M.
    Ben Yehuda, D.
    Finsinger, P.
    Rossi, G.
    Rocci, A.
    Siniscalchi, A.
    Barbarano, L.
    Carella, A.
    Catalano, L.
    Musto, P.
    Cerrato, C.
    Marcatti, M.
    Cavo, M.
    Patriarca, F.
    Genuardi, M.
    Redoglia, V.
    Rossini, F.
    Corradini, P.
    Nagler, A.
    Di Raimondo, F.
    Hardan, I.
    Boccadoro, M.
    HAEMATOLOGICA, 2013, 98 : 96 - 96
  • [22] Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma:: A report from the GIMEMA -: Italian multiple myeloma network
    Palumbo, Antonio
    Falco, Patrizia
    Corradini, Paolo
    Falcone, Antonietta
    Di Raimondo, Francesco
    Giuliani, Nicola
    Crippa, Claudia
    Ciccone, Giovannino
    Omede, Paola
    Ambrosini, Maria Teresa
    Gay, Francesca
    Bringhen, Sara
    Musto, Pellegrino
    Foa, Robin
    Knight, Robert
    Zeldis, Jerome B.
    Boccadoro, Mario
    Petrucci, Maria Teresa
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (28) : 4459 - 4465
  • [23] Oral lenalidomide plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma.
    Palumbo, A.
    Falco, P.
    Benevolo, G.
    Canepa, L.
    D'Ardia, S.
    Gozzetti, A.
    Nozza, A.
    Zeldis, J.
    Boccadoro, M.
    Petrucci, M. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 426S - 426S
  • [24] Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Myeloma: Kinetics of Neutropenia and Thrombocytopenia and Time-to-Event Results
    Palumbo, Antonio
    Falco, Patrizia
    Falcone, Antonietta
    Benevolo, Giulia
    Canepa, Letizia
    Gay, Francesca
    Larocca, Alessandra
    Magarotto, Valera
    Gozzetti, Alessandro
    Luraschi, Annalisa
    Morabito, Fortunato
    Nozza, Andrea
    Knight, Robert D.
    Zeldis, Jerome B.
    Boccadoro, Mario
    Petrucci, Maria Teresa
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (02): : 145 - 150
  • [25] Phase 2 clinical Trial of Oral Lenalidomide, Cyclophosphamide, and prednisone (RCP) for Newly Diagnosed Multiple Myeloma Patients
    Suvannasankha, Attaya
    Farag, Sherif
    Obryant, Robin
    Wood, Lisa I.
    Porter, Nicole
    Abonour, Rafat
    BLOOD, 2010, 116 (21) : 823 - 823
  • [26] Phase 2 Clinical Trial of Oral Lenalidomide, Cyclophosphamide, and Prednisone (RCP) for Newly Diagnosed Multiple Myeloma Patients
    Suvannasankha, Attaya
    Farag, Sherif
    O'Bryant, Robin A.
    Wood, Lisa L.
    Abonour, Rafat
    BLOOD, 2009, 114 (22) : 1125 - 1125
  • [27] Melphalan (M), prednisone (P) and lenalidomide (R) combination (MPR) for newly diagnosed multiple myeloma patients who are not candidates for stem cell transplantation.
    Roy, Vivek
    Leif, Bergsagel P.
    Jacob, Allred
    Philip, Greipp R.
    BLOOD, 2006, 108 (11) : 1016A - 1016A
  • [28] Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide
    Palumbo, A.
    Rus, C.
    Zeldis, J. B.
    Rodeghiero, F.
    Boccadoro, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (08) : 1842 - 1845
  • [29] Incidence of second primary malignancy (SPM) in melphalan-prednisone-lenalidomide combination followed by lenalidomide maintenance (MPR-R) in newly diagnosed multiple myeloma patients (pts) age 65 or older
    Palumbo, A. P.
    Delforge, M.
    Catalano, J.
    Hajek, R.
    Kropff, M.
    Petrucci, M. T.
    Yu, Z.
    Mei, J. M.
    Dimopoulos, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone In Patients ≥ 65 Years with Newly Diagnosed Multiple Myeloma (NDMM): Continuous Use of Lenalidomide Vs Fixed-Duration Regimens
    Palumbo, Antonio
    Delforge, Michel
    Catalano, John
    Hajek, Roman
    Kropff, Martin
    Petrucci, Maria Teresa
    Yu, Zhinuan
    Herbein, Lindsey
    Mei, Jay M.
    Jacques, Christian J.
    Dimopoulos, Meletios A.
    BLOOD, 2010, 116 (21) : 273 - 274
12345